Vivo Infusion

The firm acquires and operates ambulatory infusion centers — outpatient facilities that administer intravenous biologic therapies for chronic autoimmune and inflammatory conditions. These centers represent a cost-effective alternative to hospital infusion suites, capturing margin through channel-based drug-spread economics rather than facility fees. The model requires deep payer-contracting expertise and clinical quality oversight to maintain referring physician relationships.

The firm has not publicly disclosed its capital structure. The absence of SEC-registered investment-adviser filings, Form D notices, or public LP disclosures suggests a permanent capital vehicle, likely backed by a single-family-office or closed partnership rather than a blind-pool fund model. This structure matches typical single-family-office healthcare direct-investment strategies, where indefinite hold periods allow platform growth without exit-timing pressure.

Deal flow in ambulatory infusion consolidation typically originates through physician-founders seeking capital partners, pharmacy owners transitioning to biologic-focused models, and proprietary outreach to independent infusion operators. In a market without broad sell-side bidding processes, sourcing relies on relationships with referring rheumatology and gastroenterology practice groups. The firm's Denver base provides proximity to a growing population of biologic-treated patients in the Mountain West and Southwest regions.

Hospital outpatient infusion departments bill under higher-cost facility fee structures, charging commercial payers 2–3x what community-based infusion centers receive for identical drug administrations. Vivo Infusion's sites capture the spread between drug acquisition cost and the lower community-based reimbursement rate, which still generates sufficient margin when operating at scale. As health plans steer patients toward lower-cost sites through benefit design and prior authorization, community-based operators gain incremental patient-share.

The firm's focus on infusion therapy for chronic autoimmune and inflammatory conditions places it outside several adjacent healthcare niches. It does not invest in oncology infusion (distinct drug regimens and provider dynamics), hospital joint ventures (different reimbursement structure), dialysis centers (separate Medicare-driven economics), or physician practice management platforms that do not administer drugs directly. This discipline limits exposure to sectors with fundamentally different regulatory and reimbursement profiles.